RET and non-small cell lung carcinoma: These findings were corroborated by other studies where, in addition to detection of G810 solvent front mutations, off-target MET (278) or KRAS amplifications were detected in RET fusion-positive NSCLC patients who received either selpercatinib or pralsetinib, albeit at low frequency (60).